gallic acid has been researched along with Fatty Liver, Nonalcoholic in 6 studies
gallate : A trihydroxybenzoate that is the conjugate base of gallic acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nonalcoholic fatty liver disease (NAFLD) usually includes NAFL called simple hepatosteatosis and nonalcoholic steatohepatitis (NASH) called more steatohepatitis." | 5.91 | Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function. ( Liu, Z; Wang, E; Wang, J; Yang, L; Zhang, J; Zhang, W; Zhao, W, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease, sometimes ranges from simple steatosis to nonalcoholic steatohepatitis (NASH)." | 5.56 | Gallic Acid Inhibits Lipid Accumulation via AMPK Pathway and Suppresses Apoptosis and Macrophage-Mediated Inflammation in Hepatocytes. ( Iida, K; Kishimoto, Y; Kondo, K; Mabashi-Asazuma, H; Sato, A; Tanaka, M, 2020) |
| "Gallic acid (GA), a naturally abundant plant phenolic compound in vegetables and fruits, has been shown to have potent anti-oxidative and anti-obesity activity." | 3.80 | Gallic acid ameliorated impaired glucose and lipid homeostasis in high fat diet-induced NAFLD mice. ( Chao, J; Cheng, HY; Hsieh, MT; Huo, TI; Lee, MS; Liao, JW; Pao, LH; Peng, WH; Qin, XM; Tsai, JC, 2014) |
| "Gallic acid (GA) is a naturally occurring phenolic acid with metabolic disease-related clinical significance and preclinical benefits." | 1.91 | Gallic acid impairs fructose-driven de novo lipogenesis and ameliorates hepatic steatosis via AMPK-dependent suppression of SREBP-1/ACC/FASN cascade. ( Cao, P; Chen, L; Chen, X; Lu, Y; Qiu, Z; Song, Y; Yang, Y; Zhang, C; Zheng, G, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) usually includes NAFL called simple hepatosteatosis and nonalcoholic steatohepatitis (NASH) called more steatohepatitis." | 1.91 | Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function. ( Liu, Z; Wang, E; Wang, J; Yang, L; Zhang, J; Zhang, W; Zhao, W, 2023) |
| "Nonalcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease, sometimes ranges from simple steatosis to nonalcoholic steatohepatitis (NASH)." | 1.56 | Gallic Acid Inhibits Lipid Accumulation via AMPK Pathway and Suppresses Apoptosis and Macrophage-Mediated Inflammation in Hepatocytes. ( Iida, K; Kishimoto, Y; Kondo, K; Mabashi-Asazuma, H; Sato, A; Tanaka, M, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, Y | 2 |
| Zhang, C | 2 |
| Song, Y | 2 |
| Chen, L | 2 |
| Chen, X | 2 |
| Zheng, G | 2 |
| Yang, Y | 2 |
| Cao, P | 2 |
| Qiu, Z | 2 |
| Zhang, J | 1 |
| Zhang, W | 1 |
| Yang, L | 1 |
| Zhao, W | 1 |
| Liu, Z | 1 |
| Wang, E | 1 |
| Wang, J | 1 |
| Tanaka, M | 1 |
| Sato, A | 1 |
| Kishimoto, Y | 1 |
| Mabashi-Asazuma, H | 1 |
| Kondo, K | 1 |
| Iida, K | 1 |
| Huang, X | 1 |
| Xu, M | 1 |
| Shirahata, T | 1 |
| Li, W | 1 |
| Koike, K | 1 |
| Kojima-Yuasa, A | 1 |
| Yuasa, I | 1 |
| Kobayashi, Y | 1 |
| Zhang, L | 1 |
| Li, HX | 1 |
| Pan, WS | 1 |
| Khan, FU | 1 |
| Qian, C | 1 |
| Qi-Li, FR | 1 |
| Xu, X | 1 |
| Chao, J | 1 |
| Huo, TI | 1 |
| Cheng, HY | 1 |
| Tsai, JC | 1 |
| Liao, JW | 1 |
| Lee, MS | 1 |
| Qin, XM | 1 |
| Hsieh, MT | 1 |
| Pao, LH | 1 |
| Peng, WH | 1 |
6 other studies available for gallic acid and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Gallic acid impairs fructose-driven de novo lipogenesis and ameliorates hepatic steatosis via AMPK-dependent suppression of SREBP-1/ACC/FASN cascade.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Fatty Acid Synthase, Type I; Fatty Acids; Fru | 2023 |
Gallic acid impairs fructose-driven de novo lipogenesis and ameliorates hepatic steatosis via AMPK-dependent suppression of SREBP-1/ACC/FASN cascade.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Fatty Acid Synthase, Type I; Fatty Acids; Fru | 2023 |
Gallic acid impairs fructose-driven de novo lipogenesis and ameliorates hepatic steatosis via AMPK-dependent suppression of SREBP-1/ACC/FASN cascade.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Fatty Acid Synthase, Type I; Fatty Acids; Fru | 2023 |
Gallic acid impairs fructose-driven de novo lipogenesis and ameliorates hepatic steatosis via AMPK-dependent suppression of SREBP-1/ACC/FASN cascade.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Fatty Acid Synthase, Type I; Fatty Acids; Fru | 2023 |
Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function.
Topics: AMP-Activated Protein Kinases; Animals; Carcinoma, Hepatocellular; Gallic Acid; Humans; Lipid Metabo | 2023 |
Gallic Acid Inhibits Lipid Accumulation via AMPK Pathway and Suppresses Apoptosis and Macrophage-Mediated Inflammation in Hepatocytes.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Caspase 3; Caspase 7; Gallic Acid; Gene Expressio | 2020 |
Anti-steatosis compounds from leaves of Mallotus furetianus.
Topics: Gallic Acid; Glucosides; Hep G2 Cells; Humans; Hydrolyzable Tannins; Mallotus Plant; Non-alcoholic F | 2018 |
Novel hepatoprotective role of Leonurine hydrochloride against experimental non-alcoholic steatohepatitis mediated via AMPK/SREBP1 signaling pathway.
Topics: Adenylate Kinase; Animals; Choline Deficiency; Dose-Response Relationship, Drug; Gallic Acid; Hep G2 | 2019 |
Gallic acid ameliorated impaired glucose and lipid homeostasis in high fat diet-induced NAFLD mice.
Topics: Animals; Diet, High-Fat; Gallic Acid; Glucose; Homeostasis; Hypercholesterolemia; Insulin Resistance | 2014 |